Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Progression‐free survival ( · people with relapsed or refractory DLBCL Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell… (2021) · Cochrane | no estimate extracted | 9 studies · 575 participants | Very low |
Intervention NR Complete response ( · people with relapsed or refractory DLBCL Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell… (2021) · Cochrane | no estimate extracted | 13 studies · 620 participants | Very low |
Bamlanivimab vs placebo Mortality by day 30 · non‐hospitalised individuals with COVID‐19 SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 1 study · 101 participants | Low |
Bamlanivimab/etesevimab vs placebo Mortality by day 60 ‐ not reported · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab/etesevimab vs placebo Clinical progression · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab/etesevimab vs placebo Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab/etesevimab vs placebo Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.3 [0.16, 0.59] | 1 study · 1035 participants | Low |
Bamlanivimab/etesevimab vs placebo Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 1.15 [0.83, 1.59] | 1 study · 1035 participants | Low |
Bamlanivimab/etesevimab vs placebo Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 1.4 [0.45, 4.37] | 1 study · 1035 participants | Low |
Casirivimab/imdevimab vs placebo Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Clinical progression: requirement of IMV (WHO 7, 8 or 9), 1.2g · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Quality of life · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Mortality by day 60 · non‐hospitalised individuals with COVID‐19 SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: grade 3‐4 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Sotrovimab vs placebo Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.33 [0.01, 8.18] | 1 study · 583 participants | Low |
Sotrovimab vs placebo Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Sotrovimab vs placebo Clinical progression: oxygen requirement (≥ 5 WHO scale) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.11 [0.02, 0.45] | 1 study · 583 participants | Low |
Sotrovimab vs placebo Clinical progression: IMV or death (≥ 7 WHO scale) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.14 [0.01, 2.76] | 1 study · 583 participants | Low |
Sotrovimab vs placebo Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Sotrovimab vs placebo Admission to hospital or death by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.14 [0.04, 0.48] | 1 study · 583 participants | Low |
Bamlanivimab vs placebo Clinical progression/improvement of symptoms · non‐hospitalised individuals with COVID‐19 SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Sotrovimab vs placebo Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.87 [0.66, 1.16] | 1 study · 868 participants | Low |
Sotrovimab vs placebo Adverse events: grades 3 and 4 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.26 [0.12, 0.6] | 1 study · 868 participants | Low |
Sotrovimab vs placebo Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.27 [0.12, 0.63] | 1 study · 868 participants | Low |
Regdanvimab vs placebo Mortality by day 30Â · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 1 study · 1 participants | Low |
Regdanvimab vs placebo Mortality by day 60Â · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Regdanvimab vs placebo Clinical progression: development of severe symptoms (≥ 7 WHO scale, IMV) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 1 study · 1 participants | Low |
Regdanvimab vs placebo Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Regdanvimab vs placebo Admission to hospital or death by day 30Â · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.45 [0.14, 1.42] | 1 study · 204 participants | Low |
Regdanvimab vs placebo Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.96 [0.64, 1.43] | 1 study · 215 participants | Low |
Regdanvimab vs placebo Adverse events: grades 3 and 4 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 2.62 [0.52, 13.12] | 1 study · 215 participants | Low |
Bamlanivimab vs placebo Quality of life · non‐hospitalised individuals with COVID‐19 SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Regdanvimab vs placebo Serious adverse events by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 1 study · 1 participants | Low |
Bamlanivimab vs placebo Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 1.39 [0.4, 4.83] | 1 study · 314 participants | Low |
Bamlanivimab vs placebo Mortality by day 90 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | HR 1.09 [0.49, 2.43] | 1 study · 314 participants | Low |
Bamlanivimab vs placebo Clinical progression: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7) · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 1.17 [0.75, 1.85] | 1 study · 311 participants | Very low |
Bamlanivimab vs placebo Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Time to hospital discharge up to 26.10.2020, absolute effects for day 10 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | HR 0.97 [0.76, 1.18] | 1 study · 314 participants | Low |
Bamlanivimab vs placebo Adverse events: grades 3 and 4 by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 1.27 [0.81, 1.98] | 1 study · 314 participants | Low |
Bamlanivimab vs placebo Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.93 [0.27, 3.14] | 1 study · 314 participants | Low |
Casirivimab/imdevimab vs usual care alone Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.94 [0.87, 1.02] | 1 study · 9785 participants | Moderate |
Casirivimab/imdevimab vs usual care alone Mortality by day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Admission to hospital by day 30 · non‐hospitalised individuals with COVID‐19 SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.17 [0.02, 1.33] | 1 study · 257 participants | Low |
Casirivimab/imdevimab vs usual care alone Clinical progression: need for IMV or death (WHO ≥ 7) · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.96 [0.9, 1.04] | 1 study · 9198 participants | Moderate |
Casirivimab/imdevimab vs usual care alone Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs usual care alone Hospital discharge alive by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 1.01 [0.98, 1.04] | 1 study · 9785 participants | Moderate |